Peptide Research Database

GLP-1 Receptor Agonists

For Research Use Only. Not for Human or Veterinary Use.

Overview

Incretin-based receptor agonists studied in metabolic research — the dual GIP/GLP-1 agonist tirzepatide, the triple GIP/GLP-1/glucagon agonist retatrutide and the selective GLP-1 agonist semaglutide, with a side-by-side comparison matrix.

CompoundClassMechanismPrimary research targets
TirzepatideGIP/GLP-1 dual agonistGIP / GLP-1 dual agonistType-2-diabetes and obesity metabolic research
RetatrutideGIP/GLP-1/GCGR triagonistGIP / GLP-1 / glucagon triple agonistObesity and energy-expenditure research
SemaglutideGLP-1 receptor agonistSelective GLP-1 agonistGlycemic control, weight and cardiovascular research

Mechanism of Action

GLP-1 receptor agonists bind and activate the GLP-1 receptor (GLP-1R) — a class-B G-protein-coupled receptor expressed in the pancreas, brain, gastrointestinal tract and peripheral tissues — coupling through Gαs to raise cAMP. Endogenous GLP-1 is released by intestinal L-cells after eating.

  • Pancreatic β-cells: glucose-dependent insulin secretion
  • Pancreatic α-cells: suppression of glucagon release
  • Stomach: slowed gastric emptying
  • Brain: increased satiety and reduced appetite
  • Adipose / energy: enhanced lipolysis and energy expenditure (via the GIP and glucagon arms)
  • Heart: cardioprotective effects studied in outcome trials

Receptor binding affinities — which receptors each compound engages (approximate EC50 from published receptor pharmacology):

CompoundGLP-1RGIP receptorGlucagon receptor
TirzepatideActive (~0.06 nM)Active (~0.29 nM)Inactive
RetatrutideActive (~0.09 nM)Active (~0.12 nM)Active (~0.26 nM)
SemaglutideActive (~0.04 nM)InactiveInactive

Pharmacological Comparison

ParameterTirzepatideRetatrutideSemaglutide
Half-life~ 5 days~ 6 days~ 7 days (oral ~1 week)
RouteSubcutaneous (weekly)Subcutaneous (weekly)Subcutaneous (weekly) / oral (daily)
Bioavailability~ 80% (SC)~ 75% (SC)~ 89% (SC) / ~1% (oral)
Molecular weight4813.5 Da≈ 4840.6 Da4113.6 Da
Time to peak (Tmax)8–24 h12–24 h12–24 h
Metabolism / clearanceProteolytic degradationProteolytic degradationProteolytic degradation

Research Evidence Summary

Preclinical research:

Tirzepatide

Superior weight loss and glycemic control versus selective GLP-1R agonists in rodent models; dual GIP agonism enhances energy expenditure (Coskun et al., 2018).

Retatrutide

Additive triple-agonism effects on body-weight reduction and glucose tolerance in diet-induced obese mice (Coskun et al., 2022).

Semaglutide

Dose-dependent HbA1c and body-weight reductions across preclinical models; arcuate-nucleus GLP-1R mediates appetite suppression (Secher et al., 2014).

Published research — clinical-trial programs (headline results are established published data):

Trial programPhaseFocusReference
SURPASS (Tirzepatide)Phase 3Glycemic control in type-2-diabetes; head-to-head vs semaglutideFrías JP et al., Lancet 2021
SURMOUNT (Tirzepatide)Phase 3Body-weight reduction in obesityJastreboff AM et al., NEJM 2022
TRIUMPH (Retatrutide)Phase 2/3Body-weight reduction in obesityJastreboff AM et al., NEJM 2023
STEP (Semaglutide)Phase 3Body-weight reduction in obesityWilding JPH et al., NEJM 2021
SUSTAIN-6 / SELECT (Semaglutide)Phase 3Cardiovascular outcomesMarso SP et al., NEJM 2016

Dosing Reference

Reconstitution-oriented reference figures for laboratory research only — not human dosing guidance.

CompoundTypical research doseReconstitutionStorage
Tirzepatide0.25–2.0 mg (SC weekly)Bacteriostatic water2–8°C after reconstitution
Retatrutide0.25–1.2 mg (SC weekly)Bacteriostatic water2–8°C after reconstitution
Semaglutide0.25–2.4 mg (SC weekly)Bacteriostatic water2–8°C after reconstitution

Physicochemical Properties

PropertyTirzepatideRetatrutideSemaglutide
SolubilityWater-solubleWater-solubleWater-soluble
logP~ 4.8~ 4.9~ 4.5
pKa~ 4.2~ 4.3~ 4.1
Isoelectric point (pI)~ 5.0~ 4.9~ 4.7
Molecular weight4813.5 Da≈ 4840.6 Da4113.6 Da

Selected References

  • Coskun T, et al. Dual GIP/GLP-1 agonist tirzepatide. Diabetes, 2018.
  • Frías JP, et al. Tirzepatide versus semaglutide (SURPASS-2). The Lancet, 2021.
  • Jastreboff AM, et al. Tirzepatide for obesity (SURMOUNT-1). NEJM, 2022.
  • Jastreboff AM, et al. Retatrutide for obesity. NEJM, 2023.
  • Marso SP, et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). NEJM, 2016.
  • Wilding JPH, et al. Once-weekly semaglutide for obesity (STEP-1). NEJM, 2021.

Need research-grade peptides?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote